<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10038015</article-id><article-id pub-id-type="pmcid-ver">PMC10038015.2</article-id><article-id pub-id-type="pmcaid">10038015</article-id><article-id pub-id-type="pmcaiid">10408258</article-id><article-id pub-id-type="pmid">36692880</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2022.52381</article-id><article-id pub-id-type="publisher-id">zoi221489</article-id><article-version article-version-type="pmc-version">2</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Substance Use and Addiction</subject></subj-group></article-categories><title-group><article-title>Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic</article-title><alt-title alt-title-type="headline">Telemedicine Use and Quality of OUD Treatment During the COVID-19 Pandemic</alt-title><alt-title alt-title-type="running-head">Telemedicine Use and Quality of OUD Treatment During the COVID-19 Pandemic</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hailu</surname><given-names initials="R">Ruth</given-names></name><degrees>AB</degrees><xref rid="zoi221489aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mehrotra</surname><given-names initials="A">Ateev</given-names></name><degrees>MD</degrees><xref rid="zoi221489aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi221489aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huskamp</surname><given-names initials="HA">Haiden A.</given-names></name><degrees>PhD</degrees><xref rid="zoi221489aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Busch</surname><given-names initials="AB">Alisa B.</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="zoi221489aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi221489aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Barnett</surname><given-names initials="ML">Michael L.</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="zoi221489aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="zoi221489aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="zoi221489aff1"><label>1</label>Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts</aff><aff id="zoi221489aff2"><label>2</label>Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts</aff><aff id="zoi221489aff3"><label>3</label>McLean Hospital, Belmont, Massachusetts</aff><aff id="zoi221489aff4"><label>4</label>Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts</aff><aff id="zoi221489aff5"><label>5</label>Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women&#8217;s Hospital, Boston, Massachusetts</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> December 3, 2022.</p><p content-type="published-online"><bold>Published:</bold> January 24, 2023. doi:<uri content-type="doi">10.1001/jamanetworkopen.2022.52381</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2023 Hailu R et al. <italic toggle="yes">JAMA Network Open</italic>.</p><corresp id="zoi221489cor1"><bold>Corresponding Author:</bold> Michael L. Barnett, MD, MS, Harvard T.H. Chan School of Public Health, Department of Health Policy and Management, 677 Huntington Ave, Kresge 411, Boston, MA 02115 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mbarnett@hsph.harvard.edu">mbarnett@hsph.harvard.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Barnett and Ms Hailu had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Busch and Barnett contributed equally to this manuscript.</p><p><italic toggle="yes">Concept and design:</italic> All authors.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Hailu.</p><p><italic toggle="yes">Critical revision of the manuscript for important intellectual content:</italic> All authors.</p><p><italic toggle="yes">Statistical analysis:</italic> Hailu, Barnett.</p><p><italic toggle="yes">Obtained funding:</italic> Mehrotra, Huskamp.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Mehrotra, Huskamp, Busch.</p><p><italic toggle="yes">Supervision:</italic> Mehrotra, Busch, Barnett.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Mehrotra reported receiving personal fees from the Commonwealth of Massachusetts, Pew Charitable Trust, Sanofi Pasteur, Black Opal Ventures, and Office of the Assistant Secretary for Planning and Evaluation outside the submitted work. Dr Barnett reported being an expert witness for US government plaintiffs in litigation against opioid manufacturers. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by grant K23 AG058806 from the National Institute on Aging of the National Institutes of Health (Dr Barnett) and by grants R01 DA048533 and P30 DA035772 from the National Institute on Drug Abuse (Drs Mehrotra, Huskamp, and Busch).</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI221489-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-01-24T10:00"><day>24</day><month>1</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2023</year></pub-date><volume>6</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">442699</issue-id><elocation-id>e2252381</elocation-id><history><date date-type="received"><day>23</day><month>8</month><year>2022</year></date><date date-type="accepted"><day>3</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>24</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-09 10:25:10.220"><day>09</day><month>08</month><year>2023</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">10038015</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2022.52381</article-id><article-id pub-id-type="manuscript-id">NIHMS1874607</article-id><article-version>1</article-version><pub-date><day>03</day><month>01</month><year>2023</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">10408258</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2022.52381</article-id><article-version>2</article-version><pub-date><day>24</day><month>01</month><year>2023</year></pub-date></event></pub-history><permissions><copyright-statement>Copyright 2023 Hailu R et al. <italic toggle="yes">JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamanetwopen-e2252381.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamanetwopen-e2252381.pdf">jamanetwopen-e2252381.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.52381"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study assesses the level of telehealth implementation and its outcomes among office-based clinicians who provide outpatient opioid use disorder care.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi221489-1"><title>Question</title><p>Is clinician telemedicine use during the COVID-19 pandemic associated with differences in care for opioid use disorder (OUD)?</p></sec><sec id="ab-zoi221489-2"><title>Findings</title><p>In this cohort study of 11&#8201;801 patients with OUD with commercial insurance or Medicare Advantage coverage, there were no significant differences in visit frequency, initiation of medications for OUD, or OUD-related adverse outcomes between those who were treated by clinicians with high vs low telemedicine use across the prepandemic and pandemic periods.</p></sec><sec id="ab-zoi221489-3"><title>Meaning</title><p>This study found no evidence that telemedicine was unsafe or overused or was associated with increased access to or improved quality of OUD care, suggesting that telemedicine may be a comparable alternative to in-person OUD care.</p></sec></abstract><abstract><sec id="ab-zoi221489-4"><title>Importance</title><p>Little is known about the potential implications of the rapid transition to telehealth during the COVID-19 pandemic for treatment of opioid use disorder (OUD).</p></sec><sec id="ab-zoi221489-5"><title>Objective</title><p>To examine the association between telemedicine adoption during the COVID-19 pandemic and indicators of OUD treatment quality.</p></sec><sec id="ab-zoi221489-6"><title>Design, Setting, and Participants</title><p>This cohort study analyzed deidentified administrative claims data from OptumLabs Data Warehouse. Claims for telemedicine visits were included for both the prepandemic period (March 14, 2019, to March 13, 2020) and pandemic period (March 14, 2020, to March 13, 2021). Patients with OUD and continuous enrollment in either commercial insurance or Medicare Advantage plans were included. Clinicians who provided office-based OUD care were included and categorized into low, medium, or high telemedicine use groups. Patients were attributed to the clinician (and corresponding telemedicine use group) from whom they received a plurality of OUD visits.</p></sec><sec id="ab-zoi221489-7"><title>Main Outcomes and Measures</title><p>The 4 outcomes were all outpatient visits, OUD visits (in person vs telemedicine) within 90 days of an index visit, medications for OUD (MOUD) prescribing, and OUD-related clinical events (including drug overdose, inpatient detoxification and rehabilitation center stay, or injection drug use&#8211;related infections).</p></sec><sec id="ab-zoi221489-8"><title>Results</title><p>The analysis included 11&#8201;801 patients (mean [SD] age, 53.9 [15.7] years; 5902 males [50.0%]) who were treated by 1768 clinicians. Clinicians with low vs high telemedicine use conducted a mean (SD) of 2.1% (2.5%) vs 69.5% (18.6%) of their office visits virtually in the pandemic period. While telemedicine use for OUD increased significantly from the prepandemic to pandemic periods, total OUD visit volume (in person plus telemedicine) per patient episode remained stable among both high (2.6 to 2.7 visits per patient episode) and low (3.1 to 3.3 visits per patient episode) telemedicine use groups. In adjusted analyses comparing the prepandemic with pandemic periods, there was no differential change in MOUD initiation (adjusted odds ratio [OR], 1.00; 95% CI, 0.84-1.19), MOUD days&#8217; supply (differential change in days&#8217; supply, &#8211;0.27; 95% CI, &#8211;1.84 to 1.30), or OUD-related clinical events (adjusted OR, 1.01; 95% CI, 0.73-1.24) among patients who were treated by clinicians in low vs high telemedicine use groups.</p></sec><sec id="ab-zoi221489-9"><title>Conclusions and Relevance</title><p>Results of this study revealed that clinical outcomes were similar among patients who were treated by clinicians with high and low telemedicine use during the COVID-19 pandemic, suggesting that telemedicine is a comparable alternative to in-person OUD care. There was no evidence that telemedicine was associated with increased access to or improved quality of OUD treatment.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ZOI221489"><title>Introduction</title><p>Overdose deaths related to opioid use disorder (OUD) have increased rapidly in the past decade from 21&#8201;000 in 2010 to over 100&#8201;000 in 2021.<sup><xref rid="zoi221489r1" ref-type="bibr">1</xref>,<xref rid="zoi221489r2" ref-type="bibr">2</xref></sup> However, access to OUD treatment has remained limited. Medications for opioid use disorder (MOUD), which include methadone, buprenorphine, and long-acting injectable naltrexone, are considered the most effective treatments available for OUD.<sup><xref rid="zoi221489r3" ref-type="bibr">3</xref>,<xref rid="zoi221489r4" ref-type="bibr">4</xref>,<xref rid="zoi221489r5" ref-type="bibr">5</xref>,<xref rid="zoi221489r6" ref-type="bibr">6</xref>,<xref rid="zoi221489r7" ref-type="bibr">7</xref>,<xref rid="zoi221489r8" ref-type="bibr">8</xref>,<xref rid="zoi221489r9" ref-type="bibr">9</xref>,<xref rid="zoi221489r10" ref-type="bibr">10</xref></sup> However, in 2019, the National Survey on Drug Use and Health found that just 27.8% of individuals who needed OUD treatment received MOUD.<sup><xref rid="zoi221489r11" ref-type="bibr">11</xref></sup> For decades, there have been long-standing barriers to OUD care, including clinician shortages, stigma, cost, and transportation challenges.<sup><xref rid="zoi221489r12" ref-type="bibr">12</xref></sup> The situation may have worsened with the social isolation and infection control interventions during the COVID-19 pandemic, which appear to have played a role in the increased demand for OUD treatment and reduced access to in-person care.<sup><xref rid="zoi221489r13" ref-type="bibr">13</xref>,<xref rid="zoi221489r14" ref-type="bibr">14</xref></sup></p><p>Telemedicine has been proposed as a potential solution to reduced OUD treatment access, but there was little telemedicine use prior to 2020.<sup><xref rid="zoi221489r15" ref-type="bibr">15</xref></sup> During the COVID-19 pandemic, federal and state regulatory changes and expanded reimbursement for telemedicine services facilitated substantial increases in telemedicine use.<sup><xref rid="zoi221489r16" ref-type="bibr">16</xref></sup> For patients with OUD, these regulatory changes removed the requirement of the Ryan Haight Act<sup><xref rid="zoi221489r17" ref-type="bibr">17</xref></sup> to meet with a clinician in person before initiating MOUD.<sup><xref rid="zoi221489r18" ref-type="bibr">18</xref>,<xref rid="zoi221489r19" ref-type="bibr">19</xref></sup> In preliminary qualitative and survey research, OUD clinicians reported that telemedicine has led to increased access to buprenorphine and higher rates of MOUD initiation,<sup><xref rid="zoi221489r20" ref-type="bibr">20</xref>,<xref rid="zoi221489r21" ref-type="bibr">21</xref>,<xref rid="zoi221489r22" ref-type="bibr">22</xref>,<xref rid="zoi221489r23" ref-type="bibr">23</xref></sup> in part by removing transportation barriers and relieving the burdens of those with competing demands, such as child care and work.<sup><xref rid="zoi221489r24" ref-type="bibr">24</xref>,<xref rid="zoi221489r25" ref-type="bibr">25</xref></sup> While telemedicine for OUD may provide these benefits, there are limited national, empirical studies on the benefits or drawbacks of this shift in care delivery.<sup><xref rid="zoi221489r26" ref-type="bibr">26</xref>,<xref rid="zoi221489r27" ref-type="bibr">27</xref></sup> More evidence is needed to inform the ongoing debate about regulations and payment for OUD treatment after the COVID-19 public health emergency ends.<sup><xref rid="zoi221489r28" ref-type="bibr">28</xref></sup></p><p>The shift in care delivery during the COVID-19 pandemic toward widespread use of telemedicine provides an opportunity to address this knowledge gap. In this cohort study, we used a national database of commercially insured individuals to examine the association between telemedicine adoption during the COVID-19 pandemic and indicators of OUD treatment quality. We used a difference-in-differences methodologic approach, which reduces bias due to nonrandom patient selection into intervention or control groups. Specifically, we compared patients who received OUD treatment from clinicians with high or medium vs low telemedicine use in the pandemic period, adjusting for the outcomes experienced by patients treated by these clinicians during the prepandemic period.</p></sec><sec id="H1-2-ZOI221489"><title>Methods</title><sec id="H2-1-ZOI221489"><title>Data Sources</title><p>For this longitudinal retrospective cohort study, we used deidentified claims data from the OptumLabs Data Warehouse, which contains a national data set of medical claims and enrollment records for individuals with commercial insurance or Medicare Advantage coverage that is linked to county-level characteristics from the US Census Bureau. This study was approved by the institutional review board at Harvard Medical School, which waived the informed consent requirement because the study was non&#8211;human participant review. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guideline.</p><p>We included claims for telemedicine visits from March 14, 2019, to March 13, 2021, allowing for 1 year before and 1 year after the start of the US declaration of the COVID-19 Public Health Emergency. Loosening of telemedicine restrictions by the Centers for Medicare &amp; Medicaid Services happened soon after the public health emergency declaration.<sup><xref rid="zoi221489r16" ref-type="bibr">16</xref></sup> March 14, 2019, to March 13, 2020, was labeled as the prepandemic period, and March 14, 2020, to March 13, 2021, was labeled as the pandemic period.</p></sec><sec id="H2-2-ZOI221489"><title>Clinician Sample</title><p>Clinicians functioned as the unit of treatment assignment. The study was limited to clinicians who were most likely to be office-based (ie, nonopioid treatment program) MOUD prescribers: primary care physicians, psychiatrists, nurse practitioners, anesthesiologists (representing pain medicine specialists), rehabilitation medicine clinicians, neurologists, pediatricians, and obstetricians and gynecologists. We included prescription fills for all possible MOUD in addition to claims for facility-administered medications (eTable 1 in <xref rid="note-ZOI221489-1-s" ref-type="supplementary-material">Supplement 1</xref>). We defined a MOUD prescriber as a clinician with 1 or more MOUD claims in both the prepandemic and pandemic periods. We focused on buprenorphine (long-acting injectable or oral preparations with naloxone) and naltrexone because they are both available via typical office-based practice, while methadone for OUD care can be dispensed only through opioid treatment programs.</p></sec><sec id="H2-3-ZOI221489"><title>Defining OUD Visits and Telemedicine Exposure</title><p>The study sample was composed of patients with OUD with outpatient episodes of care. We defined outpatient visits using Healthcare Common Procedure Coding System (HCPCS) codes that are specific to clinician offices (eTable 2 in <xref rid="note-ZOI221489-1-s" ref-type="supplementary-material">Supplement 1</xref>), which excluded, for example, emergency departments, hospital inpatient units, nursing homes, and dialysis facilities. We identified individuals with OUD if they had (1) at least 2 outpatient claims with an <italic toggle="yes">International Statistical Classification of Diseases and Related Health Problems, Tenth Revision</italic> (<italic toggle="yes">ICD-10</italic>) code for OUD (F11.1, F11.2, or F11.9) in any diagnosis field, (2) at least 1 inpatient claim and at least 1 outpatient claim with an <italic toggle="yes">ICD-10</italic> code for OUD, or (3) at least 1 inpatient or outpatient claim with an <italic toggle="yes">ICD-10</italic> code for OUD and at least 1 claim with a confirmatory event (opioid overdose; hepatitis C, an infection potentially secondary to injection drug use; or inpatient detoxification or rehabilitation treatment [definitions are provided in eTable 3 in <xref rid="note-ZOI221489-1-s" ref-type="supplementary-material">Supplement 1</xref>]) within 90 days before or after the claim with an OUD diagnosis.</p><p>Among individuals meeting any of these criteria, the earliest observed visit for OUD after a 90-day clean period (no claims for OUD care, MOUD pharmacy, or HCPCS codes) was considered to be the index OUD visit. Treatment episodes for OUD were defined by all claims occurring within 90 days after the index visit. The same patient could have episodes of care in both the prepandemic and pandemic periods, but we included just 1 episode of care per period. For each episode, patients were attributed to the clinician from whom they received a plurality of their OUD visits during that episode. Patients in the sample were also required to have continuous enrollment in medical and pharmacy benefit for at least 90 days before and after the episode index visit. This requirement allowed us to observe their OUD care use, which was necessary to define an index episode after a clean period and to define use that occurred in the 90-day OUD episodes. The full flow chart of the cohort study design is provided in the eFigure in <xref rid="note-ZOI221489-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p><p>We categorized clinicians according to their proportion of telemedicine use during the pandemic period. Telemedicine visits were identified through modifiers GT, GQ, or 95 on eligible outpatient services or <italic toggle="yes">Current Procedural Terminology</italic> codes 99441 to 99443. Clinicians were then separated into tertiles (low, medium, and high telemedicine use) based on the proportion of all outpatient visits (OUD and non-OUD) conducted by each clinician via telemedicine. We defined clinician telemedicine use by measuring telemedicine use for all outpatient visits (ie, not limited to OUD, using the same HCPCS codes [eTable 2 in <xref rid="note-ZOI221489-1-s" ref-type="supplementary-material">Supplement 1</xref>]) to avoid potential misclassification due to small sample sizes of OUD visits among clinicians. Telemedicine use across all outpatient visits was highly correlated with telemedicine use limited to OUD visits among clinicians (Pearson &#961;&#8201;=&#8201;0.71). Patients with OUD were assigned to the telemedicine use group (high, medium, or low) of their assigned clinician. We used clinician telemedicine group as the key exposure variable, as opposed to comparing in-person with telemedicine care at the visit level, to avoid selection bias by indication due to a clinician using telemedicine for specific reasons within their own patient population.</p></sec><sec id="H2-4-ZOI221489"><title>Study Outcomes</title><p>We examined 4 outcomes: all outpatient visits, OUD visits, MOUD prescribing, and OUD-related clinical events. For outpatient visits, we captured total, in-person, and telemedicine visit volumes. We then captured total, in-person, and telemedicine OUD visits within 90 days of an index visit. For MOUD prescribing, consistent with a previous study,<sup><xref rid="zoi221489r7" ref-type="bibr">7</xref></sup> we defined 2 measures of MOUD initiation: (1) the proportion of patients with OUD with initiation within 90 days of the index visit, and (2) the proportion of patients with OUD with initiation within 14 days of the index visit. Retention of MOUD was defined as at least 1 additional MOUD fill within 30 to 90 days of initiation among those with initiation within 14 days of the index visit. We calculated the mean days&#8217; supply of MOUD for fills during the 90-day episode of care (shifting overlapping days forward) across all patients as well as just for those who had at least 1 fill within 14 days. For OUD-related clinical events, we captured the percentage of patients who had a drug overdose, inpatient detoxification or rehabilitation center stay, or an infection potentially secondary to injection drug use within 90 days of the index visit (eTable 3 in <xref rid="note-ZOI221489-1-s" ref-type="supplementary-material">Supplement 1</xref>). For a full description of the outcomes, see eTable 5 in <xref rid="note-ZOI221489-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p></sec><sec id="H2-5-ZOI221489"><title>Study Covariates</title><p>We captured age group (18-35, 36-50, 51-65, and &#8805;66 years), documented sex, and insurance type (commercial or Medicare Advantage) from enrollment data in the OptumLabs Data Warehouse. We defined rural-urban classifications using the rural-urban commuting area codes (metropolitan, micropolitan, small town, and rural),<sup><xref rid="zoi221489r29" ref-type="bibr">29</xref></sup> and county-level quartiles of race (percentage of population with White race) and poverty indicators (median household income) were identified from the US Census Bureau data.<sup><xref rid="zoi221489r30" ref-type="bibr">30</xref></sup> Race and ethnicity data were not available in the database. We used US Census Bureau data on county-level percentage of White residents because other race and ethnicity indicators at the county level were colinear with one another in regression modeling. We separated the counties into quartiles and linked them to patients according to the county listed in their claims. Additionally, we captured clinician specialty (primary care, psychiatry, registered nurse special service, anesthesiology, rehabilitation medicine, and other [neurology, pediatrics, and obstetrics and gynecology]).</p></sec><sec id="H2-6-ZOI221489"><title>Statistical Analysis</title><p>We used &#967;<sup>2</sup> tests to assess for bivariate differences between patients assigned to clinicians with low, medium, or high telemedicine use during the prepandemic and pandemic periods. To estimate the association between clinician telemedicine use and patient outcomes, we used a difference-in-differences approach.</p><p>For each outcome, we compared the changes in the prepandemic and pandemic periods between the patients seen by clinicians with low telemedicine use (ie, control group) and patients seen by clinicians with medium or high telemedicine use (ie, intervention groups). We compared the prepandemic and pandemic periods as 2 time points rather than as longitudinal rates per month or quarter to maximize statistical power for the smallest possible minimum detectable effect size for telemedicine. We estimated separate patient-level linear models (for visit rates and days&#8217; supply) or logistic models (for binary outcomes, such as MOUD overdose) for each outcome, including indicators for telemedicine use group (high or medium vs low as reference), pandemic period, and an interaction term of the 2 variables, adjusting for clinician specialty and all patient characteristics. The key variable of interest in each difference-in-differences regression was the coefficient for the interaction term, which represented the differential change in each outcome that was attributable to clinician telemedicine use during the pandemic period. We clustered SEs at the clinician level.</p><p>Analyses were performed in SAS, version 9.4 (SAS Institute Inc). The 95% CIs of reported estimates reflected 0.025 in each tail or <italic toggle="yes">P</italic>&#8201;&#8804;&#8201;.05, which indicated statistical significance. <italic toggle="yes">P</italic> values were 2-sided. In the sensitivity analysis, we repeated the main analyses and additionally required continuous enrollment in the behavioral health plan, but there was no difference in adjusted outcomes.</p></sec></sec><sec id="H1-3-ZOI221489"><title>Results</title><sec id="H2-7-ZOI221489"><title>Study Sample</title><p>The study sample contained 1768 clinicians who treated a total of 11 801 patients, including 5990 patients (50.8%) with an episode in the prepandemic period and 5811 (49.2%) with an episode in the pandemic period (<xref rid="zoi221489t1" ref-type="table">Table 1</xref> and <xref rid="zoi221489t2" ref-type="table">Table 2</xref>). The mean (SD) patient age was 53.9 (15.7) years, and 5899 patients (50.0%) were female and 5902 (50.0%) were male (<xref rid="zoi221489t1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="zoi221489t1" orientation="portrait"><label>Table 1. </label><caption><title>Patient and Clinician Characteristics</title></caption><table frame="hsides" rules="groups"><col width="36.46%" span="1"/><col width="15.64%" span="1"/><col width="14.6%" span="1"/><col width="14.6%" span="1"/><col width="9.38%" span="1"/><col width="9.32%" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)</th><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Low vs medium <italic toggle="yes">P</italic> value<xref rid="zoi221489t1n1" ref-type="table-fn"><sup>a</sup></xref></th><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Low vs high <italic toggle="yes">P</italic> value</th></tr><tr><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Clinician Telemedicine Use Group</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Low</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Medium</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">High</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients with OUD (N&#8201;=&#8201;11 801)</td><td valign="top" align="left" rowspan="1" colspan="1">4197 (35.6)</td><td valign="top" align="left" rowspan="1" colspan="1">4308 (36.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3296 (27.9)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Clinicians (N&#8201;=&#8201;1768)</td><td valign="top" align="left" rowspan="1" colspan="1">589 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">590 (33.4)</td><td valign="top" align="left" rowspan="1" colspan="1">589 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td colspan="6" valign="top" align="left" scope="col" rowspan="1">
<bold>Patients</bold>
</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age group, y</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 18-35</td><td valign="top" align="left" rowspan="1" colspan="1">699 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">551 (12.8)</td><td valign="top" align="left" rowspan="1" colspan="1">608 (18.5)</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td><td rowspan="4" valign="middle" align="left" colspan="1">.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 36-50</td><td valign="top" align="left" rowspan="1" colspan="1">947 (22.6)</td><td valign="top" align="left" rowspan="1" colspan="1">927 (21.5)</td><td valign="top" align="left" rowspan="1" colspan="1">791 (24.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 51-65</td><td valign="top" align="left" rowspan="1" colspan="1">1551 (37.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1559 (36.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1153 (35.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;66</td><td valign="top" align="left" rowspan="1" colspan="1">1000 (23.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1271 (29.5)</td><td valign="top" align="left" rowspan="1" colspan="1">744 (22.6)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Documented sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">2204 (52.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2069 (48.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1629 (49.4)</td><td rowspan="2" valign="middle" align="left" colspan="1">&lt;.001</td><td rowspan="2" valign="middle" align="left" colspan="1">.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">1993 (47.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2239 (52.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1667 (50.6)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Rurality</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Metropolitan</td><td valign="top" align="left" rowspan="1" colspan="1">3376 (80.4)</td><td valign="top" align="left" rowspan="1" colspan="1">3683 (85.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2897 (87.9)</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Micropolitan</td><td valign="top" align="left" rowspan="1" colspan="1">493 (11.8)</td><td valign="top" align="left" rowspan="1" colspan="1">330 (7.7)</td><td valign="top" align="left" rowspan="1" colspan="1">262 (8.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Small town</td><td valign="top" align="left" rowspan="1" colspan="1">229 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">205 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">89 (2.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rural</td><td valign="top" align="left" rowspan="1" colspan="1">99 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">90 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (1.5)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Insurance type</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Commercial</td><td valign="top" align="left" rowspan="1" colspan="1">2092 (49.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2060 (47.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1900 (57.7)</td><td rowspan="2" valign="middle" align="left" colspan="1">0.88</td><td rowspan="2" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicare Advantage</td><td valign="top" align="left" rowspan="1" colspan="1">2105 (50.2)</td><td valign="top" align="left" rowspan="1" colspan="1">2248 (52.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1396 (42.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Median household income in county</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1 (low)</td><td valign="top" align="left" rowspan="1" colspan="1">1565 (37.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1305 (30.3)</td><td valign="top" align="left" rowspan="1" colspan="1">677 (20.5)</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td><td valign="top" align="left" rowspan="1" colspan="1">1044 (24.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1080 (25.1)</td><td valign="top" align="left" rowspan="1" colspan="1">879 (26.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3</td><td valign="top" align="left" rowspan="1" colspan="1">907 (21.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1078 (25.0)</td><td valign="top" align="left" rowspan="1" colspan="1">872 (26.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4 (high)</td><td valign="top" align="left" rowspan="1" colspan="1">681 (16.2)</td><td valign="top" align="left" rowspan="1" colspan="1">845 (19.6)</td><td valign="top" align="left" rowspan="1" colspan="1">868 (26.3)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">% White population in county<xref rid="zoi221489t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1 (low)</td><td valign="top" align="left" rowspan="1" colspan="1">449 (10.7)</td><td valign="top" align="left" rowspan="1" colspan="1">517 (12.0)</td><td valign="top" align="left" rowspan="1" colspan="1">416 (12.6)</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td><td valign="top" align="left" rowspan="1" colspan="1">1187 (28.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1328 (30.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1053 (32.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3</td><td valign="top" align="left" rowspan="1" colspan="1">1104 (26.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1346 (31.2)</td><td valign="top" align="left" rowspan="1" colspan="1">901 (27.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4 (high)</td><td valign="top" align="left" rowspan="1" colspan="1">1457 (34.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1117 (25.9)</td><td valign="top" align="left" rowspan="1" colspan="1">926 (28.1)</td></tr><tr><td colspan="6" valign="top" align="left" scope="col" rowspan="1">
<bold>Clinicians</bold>
</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Specialty</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Primary care</td><td valign="middle" align="left" rowspan="1" colspan="1">286 (48.6)</td><td valign="middle" align="left" rowspan="1" colspan="1">303 (51.4)</td><td valign="middle" align="left" rowspan="1" colspan="1">156 (26.5)</td><td rowspan="6" valign="middle" align="left" colspan="1">&lt;.001</td><td rowspan="6" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Psychiatry</td><td valign="top" align="left" rowspan="1" colspan="1">132 (22.4)</td><td valign="top" align="left" rowspan="1" colspan="1">117 (19.8)</td><td valign="top" align="left" rowspan="1" colspan="1">219 (37.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> RN special service</td><td valign="top" align="left" rowspan="1" colspan="1">59 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (8.8)</td><td valign="top" align="left" rowspan="1" colspan="1">85 (14.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anesthesiology</td><td valign="top" align="left" rowspan="1" colspan="1">61 (10.4)</td><td valign="top" align="left" rowspan="1" colspan="1">78 (13.2)</td><td valign="top" align="left" rowspan="1" colspan="1">85 (14.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rehabilitation medicine</td><td valign="top" align="left" rowspan="1" colspan="1">34 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">34 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">37 (6.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref rid="zoi221489t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">17 (2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (1.2)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: NA, not applicable; OUD, opioid use disorder; RN, registered nurse.</p><fn id="zoi221489t1n1"><label>
<sup>a</sup>
</label><p>Unadjusted <italic toggle="yes">P</italic> values were estimated using &#967;<sup>2</sup> tests.</p></fn><fn id="zoi221489t1n2"><label>
<sup>b</sup>
</label><p>Race and ethnicity data were not available in the OptumLabs Data Warehouse. US Census Bureau data on county-level percentage of White residents were used because other race and ethnicity indicators at the county level were colinear with one another in regression modeling.</p></fn><fn id="zoi221489t1n3"><label>
<sup>c</sup>
</label><p>Other specialties were&#8201;neurology, pediatrics, and obstetrics and gynecology.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="zoi221489t2" orientation="portrait"><label>Table 2. </label><caption><title>Unadjusted OUD Visits and Outcomes by Clinician Telemedicine Use Group</title></caption><table frame="hsides" rules="groups"><col width="39.59%" span="1"/><col width="10.06%" span="1"/><col width="10.07%" span="1"/><col width="10.07%" span="1"/><col width="10.07%" span="1"/><col width="10.07%" span="1"/><col width="10.07%" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Visit characteristic</th><th colspan="6" valign="top" align="left" scope="colgroup" rowspan="1">Clinician telemedicine use group and period<xref rid="zoi221489t2n1" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Low</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Medium</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">High</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Prepandemic<xref rid="zoi221489t2n2" ref-type="table-fn"><sup>b</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Pandemic<xref rid="zoi221489t2n3" ref-type="table-fn"><sup>c</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Prepandemic<xref rid="zoi221489t2n2" ref-type="table-fn"><sup>b</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Pandemic<xref rid="zoi221489t2n3" ref-type="table-fn"><sup>c</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Prepandemic<xref rid="zoi221489t2n2" ref-type="table-fn"><sup>b</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Pandemic<xref rid="zoi221489t2n3" ref-type="table-fn"><sup>c</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients with OUD, No./total No. (%)</td><td valign="top" align="left" rowspan="1" colspan="1">2095/4197 (49.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2102/4197 (50.1)</td><td valign="top" align="left" rowspan="1" colspan="1">2240/4308 (52.0)</td><td valign="top" align="left" rowspan="1" colspan="1">2068/4308 (48.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1655/3296 (50.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1641/3296 (49.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">OUD outpatient visits</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Total within 90 d after earliest visit, No.</td><td valign="top" align="left" rowspan="1" colspan="1">6445</td><td valign="top" align="left" rowspan="1" colspan="1">6848</td><td valign="top" align="left" rowspan="1" colspan="1">5910</td><td valign="top" align="left" rowspan="1" colspan="1">5442</td><td valign="top" align="left" rowspan="1" colspan="1">4387</td><td valign="top" align="left" rowspan="1" colspan="1">4424</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Telemedicine, No. (%)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">116 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1032 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">83 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2653 (60.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">OUD visits per patient episode, mean (SD) No.<xref rid="zoi221489t2n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Total</td><td valign="top" align="left" rowspan="1" colspan="1">3.1 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3.3 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">2.6 (2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2.6 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2.6 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2.7 (2.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> In-person</td><td valign="top" align="left" rowspan="1" colspan="1">3.1 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3.2 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">2.6 (2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2.1 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1.1 (2.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Telemedicine</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0.1) </td><td valign="top" align="left" rowspan="1" colspan="1">0.1 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.5 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.1 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1.6 (2.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Proportion of patients with &#8805;1 MOUD fill, %</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fill within 14 d</td><td valign="top" align="left" rowspan="1" colspan="1">15.3</td><td valign="top" align="left" rowspan="1" colspan="1">15.2</td><td valign="top" align="left" rowspan="1" colspan="1">13.8</td><td valign="top" align="left" rowspan="1" colspan="1">14.6</td><td valign="top" align="left" rowspan="1" colspan="1">14.7</td><td valign="top" align="left" rowspan="1" colspan="1">13.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fill within 90 d</td><td valign="top" align="left" rowspan="1" colspan="1">19.1</td><td valign="top" align="left" rowspan="1" colspan="1">18.5</td><td valign="top" align="left" rowspan="1" colspan="1">18.0</td><td valign="top" align="left" rowspan="1" colspan="1">18.1</td><td valign="top" align="left" rowspan="1" colspan="1">19.9</td><td valign="top" align="left" rowspan="1" colspan="1">17.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fill within 30-90 d among patients with a fill within 14 d</td><td valign="top" align="left" rowspan="1" colspan="1">76.9</td><td valign="top" align="left" rowspan="1" colspan="1">68.8</td><td valign="top" align="left" rowspan="1" colspan="1">68.2</td><td valign="top" align="left" rowspan="1" colspan="1">68.1</td><td valign="top" align="left" rowspan="1" colspan="1">75.0</td><td valign="top" align="left" rowspan="1" colspan="1">65.8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">MOUD days&#8217; supply among patients with &#8805;1 MOUD fill</td><td valign="top" align="left" rowspan="1" colspan="1">20.2</td><td valign="top" align="left" rowspan="1" colspan="1">20.5</td><td valign="top" align="left" rowspan="1" colspan="1">20.8</td><td valign="top" align="left" rowspan="1" colspan="1">20.9</td><td valign="top" align="left" rowspan="1" colspan="1">18.8</td><td valign="top" align="left" rowspan="1" colspan="1">18.2</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Proportion of patients with OUD-related event within 90 d after index visit, %</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Overdose</td><td valign="top" align="left" rowspan="1" colspan="1">2.3</td><td valign="top" align="left" rowspan="1" colspan="1">2.1</td><td valign="top" align="left" rowspan="1" colspan="1">1.7</td><td valign="top" align="left" rowspan="1" colspan="1">1.9</td><td valign="top" align="left" rowspan="1" colspan="1">1.9</td><td valign="top" align="left" rowspan="1" colspan="1">1.8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Detoxification and rehabilitation</td><td valign="top" align="left" rowspan="1" colspan="1">4.1</td><td valign="top" align="left" rowspan="1" colspan="1">3.4</td><td valign="top" align="left" rowspan="1" colspan="1">2.3</td><td valign="top" align="left" rowspan="1" colspan="1">2.0</td><td valign="top" align="left" rowspan="1" colspan="1">3.0</td><td valign="top" align="left" rowspan="1" colspan="1">3.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Injection-related infection</td><td valign="top" align="left" rowspan="1" colspan="1">9.0</td><td valign="top" align="left" rowspan="1" colspan="1">10.2</td><td valign="top" align="left" rowspan="1" colspan="1">8.3</td><td valign="top" align="left" rowspan="1" colspan="1">8.3</td><td valign="top" align="left" rowspan="1" colspan="1">9.8</td><td valign="top" align="left" rowspan="1" colspan="1">7.9</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any OUD-related event</td><td valign="top" align="left" rowspan="1" colspan="1">14.7</td><td valign="top" align="left" rowspan="1" colspan="1">14.6</td><td valign="top" align="left" rowspan="1" colspan="1">11.4</td><td valign="top" align="left" rowspan="1" colspan="1">11.7</td><td valign="top" align="left" rowspan="1" colspan="1">14.0</td><td valign="top" align="left" rowspan="1" colspan="1">12.1</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: MOUD, medication for opioid use disorder; OUD, opioid use disorder.</p><fn id="zoi221489t2n1"><label>
<sup>a</sup>
</label><p>The number of clinicians was 589 in the low, 590 in the medium, and 589 in the high telemedicine group.</p></fn><fn id="zoi221489t2n2"><label>
<sup>b</sup>
</label><p>Prepandemic period: March 14, 2019, to March 13, 2020.</p></fn><fn id="zoi221489t2n3"><label>
<sup>c</sup>
</label><p>Pandemic period: March 14, 2020, to March 13, 2021.</p></fn><fn id="zoi221489t2n4"><label>
<sup>d</sup>
</label><p>Refers to the total number of OUD visits a patient had in their 90-day episode.</p></fn></table-wrap-foot></table-wrap><p>Regardless of telemedicine use group, the highest proportion of patients were aged 51 to 65 years (37.0% in the low use and 35.0% in the high use groups). Patients seen by clinicians with high telemedicine use were less likely to reside in the lowest-income counties compared with those whose clinicians had low telemedicine use (20.5% vs 37.3%). Primary care physicians were more likely to be in the low vs high telemedicine use group (48.6% vs 26.5%), while psychiatrists were more likely to be in the high vs low use group (22.4% vs 37.2%) (<xref rid="zoi221489t1" ref-type="table">Table 1</xref>).</p></sec><sec id="H2-8-ZOI221489"><title>Outpatient and OUD Visits </title><p>In the pandemic period, clinicians with low telemedicine use conducted a mean (SD) of 2.1% (2.5%) of all office visits (not just OUD visits) via telemedicine, while clinicians with high telemedicine use conducted a mean (SD) of 69.5% (18.6%) of their visits virtually (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) (eTable 4 in <xref rid="note-ZOI221489-1-s" ref-type="supplementary-material">Supplement 1</xref>). Clinician telemedicine use for OUD visits followed a similar pattern: 1.7% of visits were conducted virtually among those with low use vs 60.0% among those with high use for this subset of all visits (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) (<xref rid="zoi221489t2" ref-type="table">Table 2</xref>).</p><p>The mean number of OUD visits per episode remained stable in both the low and high telemedicine use groups over time (<xref rid="zoi221489f1" ref-type="fig">Figure</xref>). Patients seen by clinicians with low telemedicine use had a mean (SD) of 3.1 (3.7) OUD visits per patient episode in the prepandemic period and 3.3 (4.1) OUD visits per patient episode during the pandemic (<xref rid="zoi221489t2" ref-type="table">Table 2</xref>). For clinicians with high telemedicine use, there was a mean (SD) of 2.6 (2.4) OUD visits per patient episode in the prepandemic period and 2.7 (2.7) visits in the pandemic period. In the adjusted model, there was no differential change in visit volume per patient from the prepandemic period to the pandemic period among clinicians with high vs low telemedicine use (differential change in OUD visit volume, &#8211;0.01; 95% CI, &#8211;0.28 to 0.26) (<xref rid="zoi221489t3" ref-type="table">Table 3</xref>).</p><fig position="float" id="zoi221489f1" fig-type="figure" orientation="portrait"><label>Figure. </label><caption><title>Unadjusted Mean Number of Opioid Use Disorder (OUD) Visits per Patient With OUD in a 12-Month Period </title><p>The low, medium, and high telemedicine use groups were based on clinicians&#8217; telemedicine use across all outpatient visits. The prepandemic period was March 14, 2019, to March 13, 2020, and the pandemic period was March 14, 2020, to March 13, 2021.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamanetwopen-e2252381-g001.jpg"/></fig><table-wrap position="float" id="zoi221489t3" orientation="portrait"><label>Table 3. </label><caption><title>Adjusted Differential Change in Continuous OUD Outcomes Among High and Medium vs Low Telemedicine Use Groups<xref rid="zoi221489t3n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="24.14%" span="1"/><col width="27.96%" span="1"/><col width="9.97%" span="1"/><col width="27.56%" span="1"/><col width="10.37%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Continuous outcome</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Medium vs low telemedicine use groups</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">High vs low telemedicine use groups</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Differential change between the prepandemic and pandemic periods (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Differential change between the prepandemic and pandemic periods (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">OUD visit volume</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Total</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;0.13 (&#8211;0.42 to 0.16)</td><td valign="top" align="left" rowspan="1" colspan="1">.38</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;0.01 (&#8211;0.28 to 0.26)</td><td valign="top" align="left" rowspan="1" colspan="1">.94</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> In person</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;0.55 (&#8211;0.85 to &#8211;0.27)</td><td valign="top" align="left" rowspan="1" colspan="1">.002</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;1.51 (&#8211;1.79 to &#8211;1.24)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Telemedicine</td><td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.37 to 0.49)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td><td valign="top" align="left" rowspan="1" colspan="1">1.51 (1.37 to 1.65)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">MOUD days&#8217; supply</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Among patients with &#8805;1 MOUD fill</td><td valign="top" align="left" rowspan="1" colspan="1">0.29 (&#8211;1.09 to 1.68)</td><td valign="top" align="left" rowspan="1" colspan="1">.68</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;0.27 (&#8211;1.84 to 1.30)</td><td valign="top" align="left" rowspan="1" colspan="1">.73</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: MOUD, medication for opioid use disorder; OUD, opioid use disorder.</p><fn id="zoi221489t3n1"><label>
<sup>a</sup>
</label><p>Continuous outcomes were modeled with linear regressions. Adjusted values in the table are the coefficient on the interaction term, representing the difference in outcomes between low vs medium and low vs high telemedicine use groups during the pandemic. Each statistical model was adjusted for age, documented sex, rurality, insurance type, median household income in county, racial demographics in county, clinician specialty, and state. We clustered SEs by state.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-9-ZOI221489"><title>MOUD Initiation and Retention</title><p>The proportion of patients seen by clinicians with low telemedicine use who initiated MOUD within 14 days of the index visit in the prepandemic and pandemic periods was 15.3% and 15.2%, respectively. The proportion of patients seen by clinicians in the high telemedicine use group were 14.7% in the prepandemic period and 13.7% in the pandemic period (adjusted odds ratio [OR], 1.00; 95% CI, 0.84-1.19) (<xref rid="zoi221489t2" ref-type="table">Table 2</xref> and <xref rid="zoi221489t4" ref-type="table">Table 4</xref>). In the low telemedicine use vs high telemedicine use groups, patients who initiated MOUD within 14 days were equally likely to have at least 1 subsequent prescription in the 30 to 90 days after the index visit in the pandemic period (68.8% vs 65.8%; adjusted OR, 0.91 [95% CI, 0.74-1.12]) (<xref rid="zoi221489t2" ref-type="table">Table 2</xref> and <xref rid="zoi221489t4" ref-type="table">Table 4</xref>). The mean (SD) days&#8217; supply for patients with at least 1 fill within 90 days of the index visit was consistent across the prepandemic and pandemic periods for clinicians in both the low (20.2 [9.0] and 20.5 [9.1] days) and high (18.8 [9.5] and 18.2 [9.7] days) telemedicine use groups (differential change in days' supply, &#8211;0.27; 95% CI, &#8211;1.84 to 1.30).</p><table-wrap position="float" id="zoi221489t4" orientation="portrait"><label>Table 4. </label><caption><title>Adjusted Differential Change in Binary OUD Outcomes Among High and Medium vs Low Telemedicine Use Groups<xref rid="zoi221489t4n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="34.2%" span="1"/><col width="21.03%" span="1"/><col width="11.87%" span="1"/><col width="20.45%" span="1"/><col width="12.45%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Binary outcome</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Medium vs low telemedicine use groups</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">High vs low telemedicine use groups</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">aOR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">aOR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">MOUD initiation and supply</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;1 MOUD within 14 d</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.87-1.16)</td><td valign="top" align="left" rowspan="1" colspan="1">.93</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 (0.84-1.19)</td><td valign="top" align="left" rowspan="1" colspan="1">.96</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;1 MOUD within 90 d</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 (0.84-1.18)</td><td valign="top" align="left" rowspan="1" colspan="1">.97</td><td valign="top" align="left" rowspan="1" colspan="1">0.91 (0.74-1.12)</td><td valign="top" align="left" rowspan="1" colspan="1">.38</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;1 MOUD fill within 30-90 d</td><td valign="top" align="left" rowspan="1" colspan="1">0.79 (0.57-1.10)</td><td valign="top" align="left" rowspan="1" colspan="1">.16</td><td valign="top" align="left" rowspan="1" colspan="1">1.09 (0.74-1.60)</td><td valign="top" align="left" rowspan="1" colspan="1">.67</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Health care use within 90 d</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Overdose</td><td valign="top" align="left" rowspan="1" colspan="1">1.12 (0.66-1.91)</td><td valign="top" align="left" rowspan="1" colspan="1">.68</td><td valign="top" align="left" rowspan="1" colspan="1">1.14 (0.72-1.83)</td><td valign="top" align="left" rowspan="1" colspan="1">.58</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Detoxification and rehabilitation</td><td valign="top" align="left" rowspan="1" colspan="1">0.92 (0.45-1.88)</td><td valign="top" align="left" rowspan="1" colspan="1">.82</td><td valign="top" align="left" rowspan="1" colspan="1">0.84 (0.53-1.34)</td><td valign="top" align="left" rowspan="1" colspan="1">.46</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Injection-related infection</td><td valign="top" align="left" rowspan="1" colspan="1">0.91 (0.71-1.16)</td><td valign="top" align="left" rowspan="1" colspan="1">.44</td><td valign="top" align="left" rowspan="1" colspan="1">0.81 (0.58-1.11)</td><td valign="top" align="left" rowspan="1" colspan="1">.19</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any OUD-related event</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.72-1.36)</td><td valign="top" align="left" rowspan="1" colspan="1">.95</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.73-1.24)</td><td valign="top" align="left" rowspan="1" colspan="1">.69</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: aOR, adjusted odds ratio; MOUD, medication for opioid use disorder; OUD, opioid use disorder.</p><fn id="zoi221489t4n1"><label>
<sup>a</sup>
</label><p>Binary outcomes were modeled with logistic regressions. Adjusted values in the table are the coefficient on the interaction term, representing the difference in outcomes between low vs medium and low vs high telemedicine use groups during the pandemic. Each statistical model was adjusted for age, documented sex, rurality, insurance type, median household income in county, racial demographics in county, clinician specialty, and state. We clustered SEs by state.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-10-ZOI221489"><title>OUD-Related Events</title><p>The proportion of patients with at least 1 OUD-related clinical event was lower in the pandemic period compared with prepandemic period for those treated by clinicians in both the low (14.7% to 14.6%) and high (14.0% to 12.1%) telemedicine use groups; in adjusted analyses, there was no differential change between groups (adjusted OR, 1.01; 95% CI, 0.73-1.24) (<xref rid="zoi221489t2" ref-type="table">Tables 2</xref> and <xref rid="zoi221489t4" ref-type="table">Table 4</xref>). There was also no difference between low and high telemedicine use groups when evaluating each OUD-related event individually. The proportion of patients with an overdose decreased from 2.3% to 2.1% in the low telemedicine use group and from 1.9% to 1.8% in the high telemedicine use groups (adjusted OR, 1.14; 95% CI, 0.72-1.83). Detoxification and rehabilitation admissions decreased from 4.1% in the prepandemic period to 3.4% in the pandemic period and remained at 3.0% in both periods in the high telemedicine use group (adjusted OR, 0.84; 95% CI, 0.53-1.34) (<xref rid="zoi221489t2" ref-type="table">Table 2</xref> and <xref rid="zoi221489t4" ref-type="table">Table 4</xref>).</p></sec></sec><sec id="H1-4-ZOI221489"><title>Discussion</title><p>In a national sample of patients with OUD with commercial insurance or Medicare Advantage coverage, we found that treatment by clinicians with high telemedicine use was not associated with a different pattern of outpatient care or OUD-related events compared with treatment by clinicians with low telemedicine use. The total number of OUD visits per episode was consistent across the prepandemic and pandemic periods regardless of telemedicine uptake, suggesting that telemedicine almost entirely substituted, rather than supplemented, care. Overall, based on measures observable in claims data, telemedicine was comparable to in-person care, with no evidence of differential harm or benefit to patients who were seen by clinicians with high and medium vs low telemedicine use.</p><p>These results suggested that using telemedicine for OUD care was not associated with significantly lower rates of MOUD initiation or refills. These findings are consistent with those of prepandemic studies<sup><xref rid="zoi221489r31" ref-type="bibr">31</xref>,<xref rid="zoi221489r32" ref-type="bibr">32</xref>,<xref rid="zoi221489r33" ref-type="bibr">33</xref></sup> showing that buprenorphine delivered virtually had comparable patient retention and medication adherence to buprenorphine delivered in person. This study extends previous literature to the COVID-19 pandemic&#8211;era of telemedicine and its clinical implementation and suggests on a larger scale that telemedicine can safely be used to expand access to OUD care. While we were unable to observe visit appropriateness, the results of this study also do not suggest that telemedicine played a role in the increase in unnecessary or inefficient health care visits, an important concern raised by critics of telemedicine expansion.<sup><xref rid="zoi221489r34" ref-type="bibr">34</xref></sup></p><p>However, we did not find evidence of differential benefit either. Higher rate of telemedicine use was not associated with increased access, as measured by visit volume, given the consistent number of OUD visits across the prepandemic and pandemic periods. Greater telemedicine use was also not associated with increased MOUD initiation, refills, or days&#8217; supply. The low rates of MOUD use both before and during the COVID-19 pandemic were consistent with rates reported in prior literature on access to OUD treatment among commercially insured populations.<sup><xref rid="zoi221489r35" ref-type="bibr">35</xref>,<xref rid="zoi221489r36" ref-type="bibr">36</xref></sup> While telemedicine access may be part of a comprehensive policy package to promote MOUD access, there is substantial progress still needed to increase access, and telemedicine alone is unlikely to be sufficient.</p><p>It is important to note that patients who received OUD care from clinicians with high telemedicine use were concentrated in metropolitan counties with higher income and lower proportion of White residents. This finding could be consistent with concerns about a digital divide separating lower-income and rural areas in the US from mainstream technological advances that require broadband internet and other resources.<sup><xref rid="zoi221489r37" ref-type="bibr">37</xref>,<xref rid="zoi221489r38" ref-type="bibr">38</xref>,<xref rid="zoi221489r39" ref-type="bibr">39</xref></sup> In addition, given that high telemedicine use was not associated with changes in OUD care, it is possible that populations with access to clinicians with high telemedicine use had more resources to begin with compared with patients who had access to clinicians with low telemedicine use. Therefore, the digital divide may be a factor in the reduced potential of telemedicine to advance treatment access if additional measures are not taken to make telemedicine availability more equitable. High telemedicine use also was associated primarily with psychiatrists, aligning with previous reports of greater telemedicine use among behavioral health clinicians.<sup><xref rid="zoi221489r40" ref-type="bibr">40</xref></sup></p><sec id="H2-11-ZOI221489"><title>Limitations</title><p>This study has several limitations. It was an observational study; thus, we can report only associations and cannot provide conclusive evidence of any causal associations. However, we mitigated the selection bias that can occur in an observational study through the difference-in-differences design. Additionally, the findings may not be generalizable to other commercially insured populations, individuals enrolled in Medicaid and other Medicare programs, and individuals without insurance (a notable population since approximately one-fifth of adults with OUD are uninsured<sup><xref rid="zoi221489r41" ref-type="bibr">41</xref></sup>). The outcomes capture only part of the complex process of access to care, and it is possible that telemedicine had benefits (or drawbacks) that we did not observe. While we were able to measure an individual&#8217;s receipt of MOUD, visit volume, and some OUD-related clinical events or adverse events, we were unable to measure receipt of long-acting buprenorphine implants and other important clinical outcomes, such as OUD relapse or patient functioning. In addition, the rates of overdose were limited to those who initiated OUD treatment and therefore were part of the cohort.</p></sec></sec><sec id="H1-5-ZOI221489"><title>Conclusions</title><p>In this cohort study, we found that after telemedicine expansion during the COVID-19 pandemic, patients with OUD experienced similar patterns of care and had similar outcomes whether they were treated by clinicians who predominantly used telemedicine or clinicians who provided in-person care. There was no evidence to suggest that telemedicine was unsafe or overused among clinicians with high vs low telemedicine use. Conversely, there was no evidence that telemedicine was associated with increased access or improved quality of care. The results of this study suggest that telemedicine is a comparable alternative for delivering care for OUD but not one that will substantially change care quality or access in the short term.</p></sec></body><back><ref-list id="REF-ZOI221489"><title>References</title><ref id="zoi221489r1"><label>1</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Ahmad</surname><given-names>FB</given-names></string-name>, <string-name name-style="western"><surname>Cisewski</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Rossen</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Sutton</surname><given-names>P</given-names></string-name></person-group>. Provisional drug overdose death counts. National Center for Health Statistics, Centers for Disease Control and Prevention. Updated February 9, <year>2022</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm</ext-link></mixed-citation></ref><ref id="zoi221489r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>O&#8217;Donnell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Mattson</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Kariisa</surname><given-names>M</given-names></string-name></person-group>. <article-title>Notes from the field: overdose deaths with carfentanil and other fentanyl analogs detected&#8212;10 states, July 2016-June 2017</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2018</year>;<volume>67</volume>(<issue>27</issue>):<fpage>767</fpage>-<lpage>768</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm6727a4</pub-id><pub-id pub-id-type="pmid">30001560</pub-id><pub-id pub-id-type="pmcid">PMC6047470</pub-id></mixed-citation></ref><ref id="zoi221489r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Bernson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Land</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study</article-title>. <source>Ann Intern Med</source>. <year>2018</year>;<volume>169</volume>(<issue>3</issue>):<fpage>137</fpage>-<lpage>145</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M17-3107</pub-id><pub-id pub-id-type="pmid">29913516</pub-id><pub-id pub-id-type="pmcid">PMC6387681</pub-id></mixed-citation></ref><ref id="zoi221489r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Deck</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wiitala</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>McFarland</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Medicaid coverage, methadone maintenance, and felony arrests: outcomes of opiate treatment in two states</article-title>. <source>J Addict Dis</source>. <year>2009</year>;<volume>28</volume>(<issue>2</issue>):<fpage>89</fpage>-<lpage>102</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10550880902772373</pub-id><pub-id pub-id-type="pmid">19340671</pub-id><pub-id pub-id-type="pmcid">PMC2743329</pub-id></mixed-citation></ref><ref id="zoi221489r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Connery</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Medication-assisted treatment of opioid use disorder: review of the evidence and future directions</article-title>. <source>Harv Rev Psychiatry</source>. <year>2015</year>;<volume>23</volume>(<issue>2</issue>):<fpage>63</fpage>-<lpage>75</lpage>. doi:<pub-id pub-id-type="doi">10.1097/HRP.0000000000000075</pub-id><pub-id pub-id-type="pmid">25747920</pub-id></mixed-citation></ref><ref id="zoi221489r6"><label>6</label><mixed-citation publication-type="book"><person-group><string-name name-style="western"><surname>Alderks</surname><given-names>CE</given-names></string-name></person-group>. <part-title>Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update)</part-title>. In: <source>The CBHSQ Report</source>. <publisher-name>Substance Abuse and Mental Health Services Administration</publisher-name>; <year>2013</year>:<fpage>1</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">29200242</pub-id></mixed-citation></ref><ref id="zoi221489r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Ameli</surname><given-names>O</given-names></string-name>, <etal/></person-group>. <article-title>Relative cost differences of initial treatment strategies for newly diagnosed opioid use disorder: a cohort study</article-title>. <source>Med Care</source>. <year>2020</year>;<volume>58</volume>(<issue>10</issue>):<fpage>919</fpage>-<lpage>926</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MLR.0000000000001394</pub-id><pub-id pub-id-type="pmid">32842044</pub-id><pub-id pub-id-type="pmcid">PMC7641182</pub-id></mixed-citation></ref><ref id="zoi221489r8"><label>8</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Orgera</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tolbert</surname><given-names>J</given-names></string-name></person-group>. Key facts about uninsured adults with opioid use disorder. Kaiser Family Foundation. July 5, <year>2019</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kff.org/uninsured/issue-brief/key-facts-about-uninsured-adults-with-opioid-use-disorder/" ext-link-type="uri">https://www.kff.org/uninsured/issue-brief/key-facts-about-uninsured-adults-with-opioid-use-disorder/</ext-link></mixed-citation></ref><ref id="zoi221489r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Ameli</surname><given-names>O</given-names></string-name>, <etal/></person-group>. <article-title>Comparative effectiveness of different treatment pathways for opioid use disorder</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>2</issue>):<elocation-id>e1920622</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.20622</pub-id><pub-id pub-id-type="pmid">32022884</pub-id><pub-id pub-id-type="pmcid">PMC11143463</pub-id></mixed-citation></ref><ref id="zoi221489r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lee</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Nunes</surname><given-names>EV</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Novo</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>(<issue>10118</issue>):<fpage>309</fpage>-<lpage>318</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(17)32812-X</pub-id><pub-id pub-id-type="pmid">29150198</pub-id><pub-id pub-id-type="pmcid">PMC5806119</pub-id></mixed-citation></ref><ref id="zoi221489r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mauro</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Gutkind</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Annunziato</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name></person-group>. <article-title>Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>3</issue>):<elocation-id>e223821</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.3821</pub-id><pub-id pub-id-type="pmid">35319762</pub-id><pub-id pub-id-type="pmcid">PMC8943638</pub-id></mixed-citation></ref><ref id="zoi221489r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mackey</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Veazie</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bourne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>K</given-names></string-name></person-group>. <article-title>Barriers and facilitators to the use of medications for opioid use disorder: a rapid review</article-title>. <source>J Gen Intern Med</source>. <year>2020</year>;<volume>35</volume>(<issue>suppl 3</issue>):<fpage>954</fpage>-<lpage>963</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-020-06257-4</pub-id><pub-id pub-id-type="pmid">33145687</pub-id><pub-id pub-id-type="pmcid">PMC7728943</pub-id></mixed-citation></ref><ref id="zoi221489r13"><label>13</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Baumgartner</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Radley</surname><given-names>DC</given-names></string-name></person-group>. <article-title>Overdose deaths surged in the first half of 2021, underscoring urgent need for action</article-title>. Commonwealth Fund. February 7, <year>2022</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.commonwealthfund.org/blog/2022/overdose-deaths-surged-first-half-2021-underscoring-urgent-need-action" ext-link-type="uri">https://www.commonwealthfund.org/blog/2022/overdose-deaths-surged-first-half-2021-underscoring-urgent-need-action</ext-link></mixed-citation></ref><ref id="zoi221489r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Vieson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yeh</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Sprague</surname><given-names>JE</given-names></string-name></person-group>. <article-title>During the COVID-19 pandemic, opioid overdose deaths revert to previous record levels in Ohio</article-title>. <source>J Addict Med</source>. <year>2022</year>;<volume>16</volume>(<issue>2</issue>):<fpage>e118</fpage>-<lpage>e122</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000874</pub-id><pub-id pub-id-type="pmid">34172625</pub-id><pub-id pub-id-type="pmcid">PMC8919935</pub-id></mixed-citation></ref><ref id="zoi221489r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Busch</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Souza</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>How is telemedicine being used in opioid and other substance use disorder treatment?</article-title><source>Health Aff (Millwood)</source>. <year>2018</year>;<volume>37</volume>(<issue>12</issue>):<fpage>1940</fpage>-<lpage>1947</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2018.05134</pub-id><pub-id pub-id-type="pmid">30633671</pub-id><pub-id pub-id-type="pmcid">PMC6671682</pub-id></mixed-citation></ref><ref id="zoi221489r16"><label>16</label><mixed-citation publication-type="webpage">Centers for Medicare &amp; Medicaid Services. <person-group><collab>Medicare telemedicine health care provider fact sheet</collab></person-group>. March 17, <year>2020</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet" ext-link-type="uri">https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet</ext-link></mixed-citation></ref><ref id="zoi221489r17"><label>17</label><mixed-citation publication-type="webpage">American Society of Addiction Medicine. Supporting access to telehealth for addiction services. September 8, <year>2020</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.asam.org/quality-care/clinical-guidelines/covid/supporting-access-to-telehealth-for-addiction-services" ext-link-type="uri">https://www.asam.org/quality-care/clinical-guidelines/covid/supporting-access-to-telehealth-for-addiction-services</ext-link></mixed-citation></ref><ref id="zoi221489r18"><label>18</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Ng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Niles</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kinderknecht</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Strohmeyer</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Olin</surname><given-names>S</given-names></string-name></person-group>. Changes in access to medication treatment during COVID-19 telehealth expansion and disparities in telehealth use for medicare beneficiaries with opioid use disorder. Office of Minority Health (OMH) Data Highlight No. 28. Centers for Medicare &amp; Medicaid Services. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cms.gov/files/document/data-highlight-jan-2022.pdf" ext-link-type="uri">https://www.cms.gov/files/document/data-highlight-jan-2022.pdf</ext-link></mixed-citation></ref><ref id="zoi221489r19"><label>19</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Ferrante</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Levine</surname><given-names>SJ</given-names></string-name></person-group>. COVID-19: DEA confirms public health emergency exception for telemedicine prescribing of controlled substances. Foley &amp; Lardner LLP. March 18, <year>2020</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.foley.com/en/insights/publications/2020/03/covid19-public-health-exception-telemedicine" ext-link-type="uri">https://www.foley.com/en/insights/publications/2020/03/covid19-public-health-exception-telemedicine</ext-link></mixed-citation></ref><ref id="zoi221489r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Clark</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wightman</surname><given-names>RS</given-names></string-name>, <etal/></person-group>. <article-title>Using telehealth to improve buprenorphine access during and after COVID-19: a rapid response initiative in Rhode Island</article-title>. <source>J Subst Abuse Treat</source>. <year>2021</year>;<volume>124</volume>:<elocation-id>108283</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2021.108283</pub-id><pub-id pub-id-type="pmid">33771282</pub-id><pub-id pub-id-type="pmcid">PMC7817486</pub-id></mixed-citation></ref><ref id="zoi221489r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Waldman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rubin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Griffin</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic</article-title>. <source>J Subst Abuse Treat</source>. <year>2021</year>;<volume>124</volume>:<elocation-id>108272</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2020.108272</pub-id><pub-id pub-id-type="pmid">33771276</pub-id><pub-id pub-id-type="pmcid">PMC7833481</pub-id></mixed-citation></ref><ref id="zoi221489r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Riedel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mehrotra</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Use of telemedicine for opioid use disorder treatment: perceptions and experiences of opioid use disorder clinicians</article-title>. <source>Drug Alcohol Depend</source>. <year>2021</year>;<volume>228</volume>:<elocation-id>108999</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.108999</pub-id><pub-id pub-id-type="pmid">34517225</pub-id><pub-id pub-id-type="pmcid">PMC8595779</pub-id></mixed-citation></ref><ref id="zoi221489r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Riedel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Initiating opioid use disorder medication via telemedicine during COVID-19: implications for proposed reforms to the Ryan Haight Act</article-title>. <source>J Gen Intern Med</source>. <year>2022</year>;<volume>37</volume>(<issue>1</issue>):<fpage>162</fpage>-<lpage>167</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-021-07174-w</pub-id><pub-id pub-id-type="pmid">34713386</pub-id><pub-id pub-id-type="pmcid">PMC8553288</pub-id></mixed-citation></ref><ref id="zoi221489r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Eaves</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Trotter</surname><given-names>R</given-names><suffix>II</suffix></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></string-name></person-group>. <article-title>Another silver lining?: anthropological perspectives on the promise and practice of relaxed restrictions for telemedicine and medication-assisted treatment in the context of COVID-19</article-title>. <source>Hum Organ</source>. <year>2020</year>;<volume>79</volume>(<issue>4</issue>):<fpage>292</fpage>-<lpage>303</lpage>. doi:<pub-id pub-id-type="doi">10.17730/1938-3525-79.4.292</pub-id><pub-id pub-id-type="pmid">33551465</pub-id><pub-id pub-id-type="pmcid">PMC7861509</pub-id></mixed-citation></ref><ref id="zoi221489r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Aronowitz</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Engel-Rebitzer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dolan</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives</article-title>. <source>Harm Reduct J</source>. <year>2021</year>;<volume>18</volume>(<issue>1</issue>):<fpage>119</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12954-021-00572-7</pub-id><pub-id pub-id-type="pmid">34823538</pub-id><pub-id pub-id-type="pmcid">PMC8614631</pub-id></mixed-citation></ref><ref id="zoi221489r26"><label>26</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Samson</surname><given-names>LW</given-names></string-name>, <string-name name-style="western"><surname>Tarazi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Turrini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sheingold</surname><given-names>S</given-names></string-name></person-group>. Medicare beneficiaries&#8217; use of telehealth in 2020: trends by beneficiary characteristics and location. Office of the Assistant Secretary for Planning and Evaluation. December 3, <year>2021</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://aspe.hhs.gov/reports/medicare-beneficiaries-use-telehealth-2020" ext-link-type="uri">https://aspe.hhs.gov/reports/medicare-beneficiaries-use-telehealth-2020</ext-link></mixed-citation></ref><ref id="zoi221489r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lin</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Fortney</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Bohnert</surname><given-names>ASB</given-names></string-name>, <string-name name-style="western"><surname>Coughlin</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Piette</surname><given-names>JD</given-names></string-name></person-group>. <article-title>Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder</article-title>. <source>J Subst Abuse Treat</source>. <year>2022</year>;<volume>133</volume>:<elocation-id>108492</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2021.108492</pub-id><pub-id pub-id-type="pmid">34175175</pub-id><pub-id pub-id-type="pmcid">PMC8627529</pub-id></mixed-citation></ref><ref id="zoi221489r28"><label>28</label><mixed-citation publication-type="webpage">National Academy of Medicine. National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic: research agenda. March <year>2021</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nam.edu/programs/action-collaborative-on-countering-the-u-s-opioid-epidemic/opioid-collaborative-agenda/" ext-link-type="uri">https://nam.edu/programs/action-collaborative-on-countering-the-u-s-opioid-epidemic/opioid-collaborative-agenda/</ext-link></mixed-citation></ref><ref id="zoi221489r29"><label>29</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Morrill</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cromartie</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>G</given-names></string-name></person-group>. Rural-urban commuting code database. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://depts.washington.edu/uwruca/index.php" ext-link-type="uri">https://depts.washington.edu/uwruca/index.php</ext-link></mixed-citation></ref><ref id="zoi221489r30"><label>30</label><mixed-citation publication-type="webpage"><person-group><collab>US Census Bureau</collab></person-group>. Explore Census data. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://data.census.gov/" ext-link-type="uri">https://data.census.gov/</ext-link></mixed-citation></ref><ref id="zoi221489r31"><label>31</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Eibl</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Gauthier</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pellegrini</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting</article-title>. <source>Drug Alcohol Depend</source>. <year>2017</year>;<volume>176</volume>:<fpage>133</fpage>-<lpage>138</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.01.048</pub-id><pub-id pub-id-type="pmid">28535455</pub-id></mixed-citation></ref><ref id="zoi221489r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Guille</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Simpson</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Douglas</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Treatment of opioid use disorder in pregnant women via telemedicine: a nonrandomized controlled trial</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>1</issue>):<elocation-id>e1920177</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.20177</pub-id><pub-id pub-id-type="pmid">32003816</pub-id><pub-id pub-id-type="pmcid">PMC7042863</pub-id></mixed-citation></ref><ref id="zoi221489r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Nickasch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lander</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective data analysis</article-title>. <source>J Addict Med</source>. <year>2017</year>;<volume>11</volume>(<issue>2</issue>):<fpage>138</fpage>-<lpage>144</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000287</pub-id><pub-id pub-id-type="pmid">28107210</pub-id><pub-id pub-id-type="pmcid">PMC5354971</pub-id></mixed-citation></ref><ref id="zoi221489r34"><label>34</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Mehrotra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Snyder</surname><given-names>G</given-names></string-name></person-group>. <article-title>Telemedicine: what should the post-pandemic regulatory and payment landscape look like?</article-title> Commonwealth Fund. August 5, 2020. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.commonwealthfund.org/publications/issue-briefs/2020/aug/telemedicine-post-pandemic-regulation?redirect_source=/publications/issue-briefs/2020/aug/telemedicine-what-should-post-pandemic-regulatory-and-payment" ext-link-type="uri">https://www.commonwealthfund.org/publications/issue-briefs/2020/aug/telemedicine-post-pandemic-regulation?redirect_source=/publications/issue-briefs/2020/aug/telemedicine-what-should-post-pandemic-regulatory-and-payment</ext-link></mixed-citation></ref><ref id="zoi221489r35"><label>35</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kilaru</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lowenstein</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Incidence of treatment for opioid use disorder following nonfatal overdose in commercially insured patients</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>5</issue>):<elocation-id>e205852</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.5852</pub-id><pub-id pub-id-type="pmid">32459355</pub-id><pub-id pub-id-type="pmcid">PMC7254182</pub-id></mixed-citation></ref><ref id="zoi221489r36"><label>36</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Busch</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Riedel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mehrotra</surname><given-names>A</given-names></string-name></person-group>. <article-title>Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>324</volume>(<issue>23</issue>):<fpage>2440</fpage>-<lpage>2442</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.21512</pub-id><pub-id pub-id-type="pmid">33320214</pub-id><pub-id pub-id-type="pmcid">PMC7739126</pub-id></mixed-citation></ref><ref id="zoi221489r37"><label>37</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Koma</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Cubanski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Neuman</surname><given-names>T</given-names></string-name></person-group>. Medicare and telehealth: coverage and use during the COVID-19 pandemic and options for the future. Kaiser Family Foundation. May 19, <year>2021</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kff.org/medicare/issue-brief/medicare-and-telehealth-coverage-and-use-during-the-covid-19-pandemic-and-options-for-the-future/" ext-link-type="uri">https://www.kff.org/medicare/issue-brief/medicare-and-telehealth-coverage-and-use-during-the-covid-19-pandemic-and-options-for-the-future/</ext-link></mixed-citation></ref><ref id="zoi221489r38"><label>38</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Patel</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Mehrotra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ganguli</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></string-name></person-group>. <article-title>Variation in telemedicine use and outpatient care during the COVID-19 pandemic in the United States</article-title>. <source>Health Aff (Millwood)</source>. <year>2021</year>;<volume>40</volume>(<issue>2</issue>):<fpage>349</fpage>-<lpage>358</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2020.01786</pub-id><pub-id pub-id-type="pmid">33523745</pub-id><pub-id pub-id-type="pmcid">PMC7967498</pub-id></mixed-citation></ref><ref id="zoi221489r39"><label>39</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Karimi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Couture</surname><given-names>SJ</given-names></string-name>, <etal/></person-group>. National survey trends in telehealth use in 2021: disparities in utilization and audio vs. video services. Office of the Assistant Secretary for Planning and Evaluation. February 1, <year>2022</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://aspe.hhs.gov/reports/hps-analysis-telehealth-use-2021" ext-link-type="uri">https://aspe.hhs.gov/reports/hps-analysis-telehealth-use-2021</ext-link></mixed-citation></ref><ref id="zoi221489r40"><label>40</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Lo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rae</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Amin</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Panchal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>BF</given-names></string-name></person-group>. Telehealth has played an outsized role meeting mental health needs during the COVID-19 pandemic. Kaiser Family Foundation. March 15, <year>2020</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kff.org/coronavirus-covid-19/issue-brief/telehealth-has-played-an-outsized-role-meeting-mental-health-needs-during-the-covid-19-pandemic/" ext-link-type="uri">https://www.kff.org/coronavirus-covid-19/issue-brief/telehealth-has-played-an-outsized-role-meeting-mental-health-needs-during-the-covid-19-pandemic/</ext-link></mixed-citation></ref><ref id="zoi221489r41"><label>41</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Orgera</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tolbert</surname><given-names>J</given-names></string-name></person-group>. Key facts about uninsured adults with opioid use disorder. Kaiser Family Foundation. July 15, <year>2019</year>. Accessed November 23, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kff.org/uninsured/issue-brief/key-facts-about-uninsured-adults-with-opioid-use-disorder/#:~:text=The%20number%20of%20deaths%20is,access%20to%20treatment%20and%20care" ext-link-type="uri">https://www.kff.org/uninsured/issue-brief/key-facts-about-uninsured-adults-with-opioid-use-disorder/#:~:text=The%20number%20of%20deaths%20is,access%20to%20treatment%20and%20care</ext-link></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI221489-1"><supplementary-material id="note-ZOI221489-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p><bold>eTable 1.</bold> Facility Medications for Opioid Use Disorder (MOUD)</p><p><bold>eTable 2.</bold> Classification of Outpatient Visits</p><p><bold>eTable 3.</bold> Confirmatory Diagnosis CPT Codes</p><p><bold>eTable 4.</bold> Outpatient Visits (OUD and Non-OUD) Outcomes</p><p><bold>eTable 5.</bold> Outcome Descriptions</p><p><bold>eFigure.</bold> OUD Cohort Creation</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e2252381-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e2252381-s002.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></back></article></pmc-articleset>